Key Points
Acoramidis (Attruby) is a tablet for adults with transthyretin amyloid cardiomyopathy, in both its hereditary and its age-related form. It keeps the transthyretin protein from falling apart; approved by the FDA in November 2024.
| Situation | How it helps | What human studies showed |
|---|---|---|
| Transthyretin amyloid cardiomyopathy | holds transthyretin together and thereby slows the formation of new amyloid | ATTRibute-CM (NEJM, 2024), 632 patients, 30 months: the primary outcome favoured the drug, win ratio 1.8 (95% CI 1.4–2.2; p<0.001); more than half the contribution came from death from any cause and cardiovascular hospitalisation — outcomes that matter in themselves [1] |
| Tolerability | adverse events as on placebo, serious ones less frequent | 98.1% versus 97.6%; serious — 54.6% versus 64.9% [1] |
| Long-term treatment | the effect holds | open-label extension of ATTRibute-CM (JAMA Cardiology, 2026) [2] |
How It Helps
What Happens to the Heart
Transthyretin is an ordinary blood protein carrying thyroid hormone and vitamin A. Normally it is assembled from four identical parts locked firmly together.
With age, or because of an inherited mutation, that lock weakens. The structure falls apart, the loose parts change shape and clump into insoluble fibrils — amyloid.
Those fibrils deposit in the heart muscle. It becomes stiff and stops relaxing properly: the heart cannot fill adequately between beats. Heart failure develops — and its distinguishing feature is that ejection fraction stays normal, which is why the disease slips past diagnosis for years.
The Hint Nature Provided
There is a variant of the transthyretin gene called T119M. In its carriers the protein holds together more firmly than usual. And — the key fact — they do not develop amyloidosis, even when a second, disease-causing mutation is present.
The experiment, in other words, has already been run: nature itself showed that if the tetramer is not allowed to fall apart, the disease does not occur.
Acoramidis is engineered to reproduce that effect chemically: it binds the four parts of the protein and holds them together. This is the rare case of a drug that was not invented from scratch but copied from an existing protection.
What the Trial Showed
▸ ATTRibute-CM: 63.7% of pairwise comparisons favoured the drug against 35.9% favouring placebo [1].
Serious events were less frequent on the drug, and the explanation is straightforward: in the placebo group the disease progressed faster, and its complications are precisely what counts as serious events.
What a Win Ratio Is and Why It Was Needed
When several outcomes matter and they are not equivalent, they cannot simply be added up: a death and metres walked in six minutes are quantities of different orders. So patients from the two groups are compared in pairs and in a strict order:
| Step | What is compared |
|---|---|
| 1 | Who lived longer |
| 2 | If there is no difference — who had fewer cardiovascular hospitalisations |
| 3 | If still equal — whose NT-proBNP was better |
| 4 | Last — who walked further in six minutes |
Each pair yields a win or a loss. A win ratio of 1.8 means the drug produced 1.8 times as many wins as losses. The point of the construction is to stop small improvements from outweighing deaths, by ranking outcomes in the order of their real importance.
Where It Sits Among Other Drugs
| Tafamidis | Acoramidis | |
|---|---|---|
| Class | Transthyretin stabiliser | Transthyretin stabiliser |
| Pivotal trial | ATTR-ACT (2018) | ATTRibute-CM (2024) |
| Form | Capsules | Tablets |
Both drugs act at the same point.
How It Is Taken
Tablets; the regimen is prescribed by the cardiologist according to the prescribing information [4], once the diagnosis is confirmed. Acoramidis adds to baseline heart failure therapy. The earlier treatment starts, the more intact heart muscle can be protected.
Who Should See a Doctor First
When to Suspect the Disease
▸ Heart failure in an older person with preserved ejection fraction and unexplained thickened heart walls.
▸ Bilateral carpal tunnel syndrome occurring some years before the cardiac symptoms — one of the most characteristic early signs.
▸ Spinal canal stenosis, rupture of the biceps tendon.
▸ Poor tolerance of standard cardiac drugs, particularly those lowering blood pressure.
The diagnosis today is made without a cardiac biopsy, using scintigraphy with bone-seeking tracers. One condition is mandatory: excluding light-chain amyloidosis, which is treated in an entirely different way.
Who It Is Not For
▸ Patients with light-chain amyloidosis: a different disease with different treatment, where delay costs more.
▸ Anyone without a confirmed diagnosis: treatment begins after scintigraphy and the exclusion of alternatives, not on suspicion.
▸ As a replacement for baseline heart failure therapy — a stabiliser adds to it rather than cancelling it.
Bottom Line
▸ Mechanism: holds transthyretin together, copying the naturally protective T119M mutation.
▸ Demonstrated in 632 patients: a win ratio of 1.8, with more than half the contribution from deaths and hospitalisations.
▸ Early diagnosis decides the outcome: the drug protects intact muscle — the earlier treatment starts, the more of it can be preserved.
Treatment can be discussed at a consultation; the drug can be ordered here.
References
1. Gillmore JD, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024;390(2):132–142. PMID 38197816
2. Soman P, et al. Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Trial. JAMA Cardiol. 2026;11(5):446–454. PMID 41911489
3. Maurer MS, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. PMID 30145929
4. ATTRUBY (acoramidis) — US Prescribing Information, BridgeBio Pharma.
Source: Acoramidis (Attruby) in Cardiac Amyloidosis: A Drug Copied From a Protective Mutation — universum.earth. Dr. Pereligyn.
